Abstracts tagged "patient-reported outcome measures"

Abstract Number: 070 • 2020 Pediatric Rheumatology Symposium
The Importance of the Patient Global Health Assessment of Disease Activity in Polyarticular Juvenile Idiopathic Arthritis
Rebecca Trachtman¹, Daniel J. Lovell ², Rula Issa ¹, Stephanie Pan ¹, Karen Wilson ¹ and Karen Onel ³, ¹Icahn School of Medicine at Mount Sinai, New York, ²Cincinnati, ³Hospital for Special Surgery, New York
Background/Purpose: Polyarticular juvenile idiopathic arthritis (pJIA) is a subtype of JIA wherein more than four joints are affected with arthritis; it is characterized by unpredictable…
Abstract Number: 104 • 2020 Pediatric Rheumatology Symposium
Patients Perspectives on Living with a Systemic Autoinflammatory Disease: Impact on Quality of Life
Mariana Correia Marques¹, Nicole Tennermann ², Sivia Lapidus ³, Grant Schulert ⁴, Jennifer Tousseau ², Rashmi Sinha ⁵, Karen Durrant ⁶, Saskya Angevare ⁷ and Fatma Dedeoglu ⁸, ¹Boston Children's Hospital, Boston, Massachusetts, ², ³The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Maplewood, ⁴Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, ⁵Systemic JIA Foundation, Cincinnati, ⁶Autoinflammatory Alliance, San Francisco, ⁷Amersfoort, Netherlands, ⁸Boston Children's Hospital, Boston
Background/Purpose: Systemic autoinflammatory diseases (SAIDs) encompass multiple clinical entities in which spontaneous inflammation occurs due to dysregulation of the innate immune response. The variability in…
Abstract Number: 453 • 2019 ACR/ARP Annual Meeting
Including Pain, Fatigue and Functionality Regularly in the Assessment of Patients with Early Rheumatoid Arthritis Separately Adds to the Evaluation of Disease Status
Sofia Pazmino¹, Anikó Lovik ², Annelies Boonen ³, Diederik De Cock ¹, Veerle Stouten ¹, Johan Joly ⁴, Kristien Van der Elst ⁵, Delphine Bertrand ¹, Rene Westhovens ⁶ and Patrick Verschueren ⁵, ¹KU Leuven, Leuven, Belgium, ²Leuven Biostatistics and Statistical Bioinformatics Center, KU Leuven, Leuven, Vlaams-Brabant, Belgium, ³Maastricht University Medical Center, Maastricht, Netherlands, ⁴University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium, ⁵University Hospital Leuven, Leuven, Belgium, ⁶University Hospitals, Leuven, Belgium
Background/Purpose: Rheumatoid arthritis (RA) level of disease activity, cannot be evaluated by a single clinical or laboratory measurement. Hence, composite indices have been created via…
Abstract Number: 1824 • 2019 ACR/ARP Annual Meeting
Perceived Stress Independently Associates with Worse Type 2 Symptoms in Systemic Lupus Erythematosus
Sarah Patterson¹, Laura Trupin ¹, Cristina Lanata ¹, Louise Murphy ², Wendy Hartogenesis ¹, Maria Dall'Era ¹, Jinoos Yazdany ³ and Patricia Katz ¹, ¹University of California, San Francisco, San Francisco, CA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: A new posited framework for categorizing patients with systemic lupus erythematosus (SLE) is the division of symptomatology into two groups: type 1 manifestations represent…
Abstract Number: 648 • 2019 ACR/ARP Annual Meeting
Patients of African Descent Score Higher on Quality of Life Indices Despite Their Known Disease Severity
Katie Zuech¹, Ly Tran ², Teresa Aberle ¹, Cristina Arriens ³, Eliza F. Chakravarty ³, Joan T. Merrill ⁴ and Judith James ³, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus (SLE) may have a significant impact on multiple dimensions of quality of life. Patient-reported outcome (PRO) tools may provide valuable insights for…
Abstract Number: 1921 • 2019 ACR/ARP Annual Meeting
Parent-Reported Medication Side-Effects and Their Impact on Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Gaëlle Chédeville¹, Michelle Batthish ², Roberta Berard ³, Roxana Bolaria ⁴, Alessandra Bruns ⁵, David Cabral ⁶, Ciaran Duffy ⁷, Kerstin Gerhold ⁸, Tommy Gerschman ⁶, Jean-Philippe Proulx-Gauthier ⁹, Alan Rosenberg ¹⁰, Dax Rumsey ¹¹, Heinrike Schmeling ¹², Natalie Shiff ¹³, Gordon Soon ¹⁴, Lori Tucker ¹⁵ and Jaime Guzman ⁶, ¹The Montreal Children's Hospital, McGill University, Montreal, Canada, ²McMaster University, Hamilton, Canada, ³Children's Hospital, London Health Sciences Centre, London, Canada, ⁴University of British Columbia, Victoria, BC, Canada, ⁵Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Université Laval, Québec, QC, Canada, ¹⁰University of Saskatchewan, Saskatoon, SK, Canada, ¹¹University of Alberta, Edmonton, AB, Canada, ¹²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹³University of Florida, Gainesville, FL, ¹⁴University of Toronto, Toronto, ON, Canada, ¹⁵British Columbia Children’s Hospital, Vancouver, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and many medications are available to control the disease. While physician-reported adverse…
Abstract Number: 833 • 2019 ACR/ARP Annual Meeting
Effect of a Mobile App to Monitor Patient Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial
Yvonne Lee¹, Fengxin Lu ², Joshua Colls ², Meredith Murray ², Dong Suh ², Jing Song ³, Julia (Jungwha) Lee ⁴, Dorothy Dunlop ⁴ and Daniel Solomon ⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, ²Brigham and Women's Hospital, Boston, MA, ³Northwestern University Feinberg School of Medicine, Worthington, OH, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Treat to target (TTT) is an effective strategy to improve outcomes in rheumatoid arthritis (RA). However, barriers to TTT include frequent clinic visits, poor…
Abstract Number: 2513 • 2019 ACR/ARP Annual Meeting
Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Laura Coates¹, Andrew Bushmakin ², Oliver FitzGerald ³, Dafna Gladman ⁴, Lara Fallon ⁵, Joseph Cappelleri ², Ming-Ann Hsu ⁶ and Philip Helliwell ⁷, ¹University of Oxford, Oxford, United Kingdom, ²Pfizer Inc, Groton, CT, ³University College Dublin, Dublin, Ireland, ⁴University of Toronto, Toronto, ON, Canada, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a complex heterogeneous disease associated with multiple domains. Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite disease activity measure…
Abstract Number: 834 • 2019 ACR/ARP Annual Meeting
Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges
Shanthini Kasturi¹, John Wong ¹, Lisa Mandl ², Timothy McAlindon ³ and Amy LeClair ¹, ¹Tufts Medical Center, Boston, ²Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ³Tufts Medical Center, Boston, MA
Background/Purpose: There is growing interest in the implementation of patient-reported outcome measures (PROMs) in clinical rheumatology to promote patient-centered care and to meet the mandates…
Abstract Number: 2514 • 2019 ACR/ARP Annual Meeting
Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Philip Helliwell¹, Andrew Bushmakin ², Dafna Gladman ³, Oliver FitzGerald ⁴, Lara Fallon ⁵, Joseph Cappelleri ², Ming-Ann Hsu ⁶ and Laura Coates ⁷, ¹University of Leeds, Leeds, United Kingdom, ²Pfizer Inc, Groton, CT, ³University of Toronto, Toronto, ON, Canada, ⁴University College Dublin, Dublin, Ireland, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: PsA is associated with multiple disease domains, requiring the use of different clinical measures and patient-reported outcomes (PROs) to assess improvements in disease activity…
Abstract Number: 835 • 2019 ACR/ARP Annual Meeting
High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients – Data from the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Lykke Midtbøll Ørnbjerg ², Herman Mann ³, Tore Kvien ⁴, Michael J. Nissen ⁵, Maria José Santos ⁶, Dan Nordström ⁷, Lennart Jacobsson ⁸, Ziga Rotar ⁹, Bjorn Gudbjornsson ¹⁰, Süleyman Serdar Koca ¹¹, Catalin Codreanu ¹², Manuel Pombo-Suarez ¹³, Irene van der Horst-Bruinsma ¹⁴, Anne Gitte Loft ¹⁵, Karel Pavelka ³, Eirik Kristianslund ¹⁶, Burkhard Moeller ¹⁷, Elsa Vieira-Sousa ¹⁸, Anna Mari Hokkanen ¹⁹, Ulf Lindström ²⁰, Matija Tomsic ²¹, Thorvardur J Love ²², Abdurrahman Tufan ²³, Ruxandra IONESCU ²⁴, Carlos Sánchez-Piedra ²⁵, Marleen van de Sande ²⁶, Gary Macfarlane ²⁷, Florenzo Iannone ²⁸, Lise Hyldstrup ², Mikkel Østergaard ²⁹ and Merete Lund Hetland ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵University Hospital Geneva, Geneva, Switzerland, ⁶Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁷Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁸Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ⁹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹⁰Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹¹Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ¹⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ¹⁷University Hospital Bern, Bern, Switzerland, ¹⁸Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ¹⁹Helsinki University Hospital, Helsinki, Finland, ²⁰University of Gothenburg, Gothenburg, Sweden, ²¹Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²²Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²³Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, ²⁴SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁵Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²⁶Amsterdam UMC, Amsterdam, Netherlands, ²⁷University of Aberdeen, Aberdeen, United Kingdom, ²⁸Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³⁰DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Discordance between baseline patient’s and evaluator’s global assessment of disease activity is common1 and may reduce the likelihood of remission following tumor necrosis factor…
Abstract Number: 2639 • 2019 ACR/ARP Annual Meeting
Comparison of Patient Self-reported Data to Physician-driven Cohorts in Patients with Eosinophilic Granulomatosis with Polyangiitis
Irena Doubelt¹, Jason Springer ², Tanaz Kermani ³, Antoine Sreih ⁴, Cristina Burroughs ⁵, David Cuthbertson ⁵, Simon Carette ¹, Nader A. Khalidi ⁶, Curry L. Koening ⁷, Carol Langford ⁸, Carol A. McAlear ⁹, Larry W. Moreland ¹⁰, Paul Monach ¹¹, Dianne Shaw ¹², Philip Seo ¹³, Ulrich Specks ¹⁴, Kalen Young ¹⁵, Steven Ytterberg ¹⁴, Peter A. Merkel ¹⁶, Christian Pagnoux ¹ and VCRC Vasculitis Clinical Research Consortium ¹⁷, ¹Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ²Kansas University Medical Center, Kansas, MO, ³University of California Los Angeles, Los Angeles, CA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of South Florida, Tampa, FL, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Utah Hospital, Salt Lake City, UT, ⁸Cleveland Clinic, Cleveland, OH, ⁹University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ¹⁰University of Pittsburgh, Pittsburgh, PA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Vasculitis Foundation, North Carolina, ¹³Johns Hopkins Medicine, Baltimore, MD, ¹⁴Mayo Clinic College of Medicine, Rochester, MN, ¹⁵Vasculitis Foundation, Kansas City, MO, ¹⁶Univeristy of Pennsylvania, Philadelphia, PA, ¹⁷University of Pennsylvania, Division of Rheumatology, philadelphia
Background/Purpose: Aligning perspectives of patients and physicians in the diagnosis and management of diseases is imperative, particularly in rare, chronic diseases such as vasculitis. We…
Abstract Number: 838 • 2019 ACR/ARP Annual Meeting
Are PROMIS Measures Associated with Minimal Disease Activity in Psoriatic Arthritis?
Juliette Yedimenko¹, Yuxuan Jin ², Alexis Ogdie ³, Jessica Walsh ⁴, Jose Scher ⁵, Soumya Reddy ⁶ and M. Elaine Husni ¹, ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Quantitative Health Science, Cleveland Clinic, Cleveland, OH, ³Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, ⁶Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Patient-reported outcomes (PROs) are an important part of clinical decision making and are frequently used in combination with objective measures of disease activity and…
Abstract Number: 2847 • 2019 ACR/ARP Annual Meeting
Testing Different Thresholds for Patient Global Assessment in Defining ACR-EULAR Boolean Remission Criteria for RA
Paul Studenic¹, David Felson ², Maarten de Wit ³, Farideh Alasti ⁴, Tanja Stamm ¹, Josef Smolen ¹ and Daniel Aletaha ¹, ¹Medical University of Vienna, Vienna, Austria, ²Boston University School of Medicine, Department of Rheumatology, Boston, ³Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁴Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria
Background/Purpose: The patient global assessment (PGA) is a core set variable to assess RA disease activity. It is strongly linked to patient-reported pain and is…
Abstract Number: 1108 • 2019 ACR/ARP Annual Meeting
Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS)
Johannes Knitza¹, Koray Tascilar ², Eva-Maria Messner ³, Marco Meyer ⁴, Diana Vossen ⁵, Almut Pulla ⁶, Philipp Bosch ⁷, Julia Kittler ⁸, Arnd Kleyer ¹, Philipp Sewerin ⁹, Johanna Mucke ¹⁰, Isabell Haase ¹¹, David Simon ¹² and Martin Krusche ¹³, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ³Department for Clinical Psychology and Psychotherapy, Ulm University, Ulm, Germany, Ulm, Germany, ⁴Asklepios Klinik Altona, Rheumatologie, Klinische Immunologie, Nephrologie, Hamburg, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Hamburg, Germany, ⁵Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St. Elisabeth-Hospital, Meerbusch, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Meerbusch, Germany, ⁶Rheinisches Rheumazentrum Meerbusch, St. Elisabeth-Hospital, Meerbusch, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Meerbusch, Germany, ⁷Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, ⁸Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Erlangen, Germany, ⁹Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ¹⁰Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Düsseldorf, Germany, ¹¹Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ¹²Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ¹³Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin, Berlin, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Berlin, Germany
Background/Purpose: Mobile applications promise to facilitate the life of patients as well as physicians. In routine practice, however, rheumatology apps are largely unknown and little…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].